{"protocolSection": {"identificationModule": {"nctId": "NCT00613951", "orgStudyIdInfo": {"id": "NN5401-1792"}, "secondaryIdInfos": [{"id": "2007-002462-35", "type": "EUDRACT_NUMBER"}], "organization": {"fullName": "Novo Nordisk A/S", "class": "INDUSTRY"}, "briefTitle": "Comparison of Two NN5401 Formulations Versus Biphasic Insulin Aspart 30, All in Combination With Metformin in Subjects With Type 2 Diabetes", "officialTitle": "A 16 Week Randomised, Open Labelled, 3-armed, Parallel Group, Treat-to-target Trial Comparing Twice Daily (BID) Injections of SIAC 30 (B), SIAC 45 (B) and NovoMix\u00ae30, All in Combination With Metformin in Subjects With Type 2 Diabetes Failing on OAD Treatment"}, "statusModule": {"statusVerifiedDate": "2017-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2008-01"}, "primaryCompletionDateStruct": {"date": "2008-08", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-08", "type": "ACTUAL"}, "studyFirstSubmitDate": "2008-01-30", "studyFirstSubmitQcDate": "2008-01-30", "studyFirstPostDateStruct": {"date": "2008-02-13", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2015-10-16", "resultsFirstSubmitQcDate": "2015-11-27", "resultsFirstPostDateStruct": {"date": "2015-12-01", "type": "ESTIMATED"}, "dispFirstSubmitDate": "2009-11-09", "dispFirstSubmitQcDate": "2009-11-09", "dispFirstPostDateStruct": {"date": "2009-11-11", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2017-02-09", "lastUpdatePostDateStruct": {"date": "2017-03-20", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Novo Nordisk A/S", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This trial is conducted in Europe. The aim of this trial is to compare two NN5401 (Soluble Insulin Analogue Combination \\[SIAC\\], insulin degludec/insulin aspart) formulations with each other and with biphasic insulin aspart 30, all in combination with metformin in insulin naive subjects with type 2 diabetes."}, "conditionsModule": {"conditions": ["Diabetes", "Diabetes Mellitus, Type 2"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 182, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "SIAC 30 (B)", "type": "EXPERIMENTAL", "interventionNames": ["Drug: insulin degludec/insulin aspart", "Drug: metformin"]}, {"label": "SIAC 45 (B)", "type": "EXPERIMENTAL", "interventionNames": ["Drug: insulin degludec/insulin aspart", "Drug: metformin"]}, {"label": "BIAsp 30", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: biphasic insulin aspart", "Drug: metformin"]}], "interventions": [{"type": "DRUG", "name": "insulin degludec/insulin aspart", "description": "Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily", "armGroupLabels": ["SIAC 30 (B)"]}, {"type": "DRUG", "name": "insulin degludec/insulin aspart", "description": "Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily", "armGroupLabels": ["SIAC 45 (B)"]}, {"type": "DRUG", "name": "biphasic insulin aspart", "description": "Treat-to-target dose titration scheme, injection s.c., twice daily", "armGroupLabels": ["BIAsp 30"]}, {"type": "DRUG", "name": "metformin", "description": "Tablets, 1500-2000 mg/daily", "armGroupLabels": ["BIAsp 30", "SIAC 30 (B)", "SIAC 45 (B)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in Glycosylated Haemoglobin (HbA1c)", "description": "Change from baseline in HbA1c after 16 weeks of treatment", "timeFrame": "Week 0, Week 16"}], "secondaryOutcomes": [{"measure": "Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)", "description": "Estimate of the overall mean of SMPG after 16 weeks of treatment. Plasma glucose measured: before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, before bedtime, at 4 am and before breakfast.", "timeFrame": "Week 16"}, {"measure": "Rate of Major and Minor Hypoglycaemic Episodes", "description": "Observed rate of major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L.", "timeFrame": "Week 0 to Week 16 + 5 days follow up"}, {"measure": "Rate of Nocturnal Major and Minor Hypoglycaemic Episodes", "description": "Rate of nocturnal major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Episodes were defined as nocturnal if the time of onset was between 23:00 (included) and 05:59 (included).", "timeFrame": "Week 0 to Week 16 + 5 days follow up"}, {"measure": "Rate of Treatment Emergent Adverse Events (AEs)", "description": "Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.", "timeFrame": "Week 0 to Week 16 + 5 days follow up"}, {"measure": "Laboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT)", "description": "Laboratory values at screening (Week -4) and at Week 16", "timeFrame": "Week -4, Week 16"}, {"measure": "Laboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT)", "description": "Laboratory values at screening (Week -4) and at Week 16", "timeFrame": "Week -4, Week 16"}, {"measure": "Laboratory Safety Parameters (Biochemistry): Serum Creatinine", "description": "Laboratory values at screening (Week -4) and at Week 16", "timeFrame": "Week -4, Week 16"}, {"measure": "Vital Signs: Diastolic Blood Pressure (BP)", "description": "Values at baseline (Week 0) and at Week 16", "timeFrame": "Week 0, Week 16"}, {"measure": "Vital Signs: Systolic Blood Pressure (BP)", "description": "Values at baseline (Week 0) and at Week 16", "timeFrame": "Week 0, Week 16"}, {"measure": "Vital Signs: Pulse", "description": "Values at baseline (Week 0) and at Week 16", "timeFrame": "Week 0, Week 16"}, {"measure": "Physical Examination", "description": "Physical examination was performed at screening (week -4), and after 8 and 16 weeks of treatment. If any new findings or deterioration in previous findings were observed during the trial, these were recorded as AEs and are therefore not presented separately as no analysis was performed.", "timeFrame": "Week -4, Week 8, Week 16"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.)\n* Insulin na\u00efve type 2 diabetes subjects (as diagnosed clinically) for at least 3 months (no previous insulin treatment or previous short term insulin treatment maximum 14 days within the last 3 months)\n* Treatment with one or two oral anti-diabetic drugs (OADs): metformin, sulfonylurea, other insulin secretagogue (e.g. repaglinide, nateglinide), alpha-glucosidase inhibitors for at least 2 months at a stable maximally tolerated dose or at least half maximally allowed dose according to locally approved summary of product characteristics (SPC)\n* HbA1c, 7.0-11.0 % (both inclusive)\n* Body Mass Index (BMI), 25.0-37.0 kg/m\\^2 (both inclusive)\n\nExclusion Criteria:\n\n* Metformin contraindication according to local practice\n* Thiazolidinedione (TZD) treatment within previous 3 months prior to Visit 1\n* Any systemic treatment with products, which in the investigator's opinion could interfere with glucose or lipid metabolism (e.g. systemic corticosteroids) within 3 months prior to randomisation\n* Subject has a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, neurological, genitourinary, or haematological system (except for conditions associated with type 2 diabetes) that, in the opinion of the investigator, may confound the results of the trial or pose additional risk in administering trial product", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "75 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Global Clinical Registry (GCR, 1452)", "affiliation": "Novo Nordisk A/S", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Novo Nordisk Investigational Site", "city": "Helsinki", "zip": "00260", "country": "Finland", "geoPoint": {"lat": 60.16952, "lon": 24.93545}}, {"facility": "Novo Nordisk Investigational Site", "city": "Kuopio", "zip": "70210", "country": "Finland", "geoPoint": {"lat": 62.89238, "lon": 27.67703}}, {"facility": "Novo Nordisk Investigational Site", "city": "Lahti", "zip": "15110", "country": "Finland", "geoPoint": {"lat": 60.98267, "lon": 25.66151}}, {"facility": "Novo Nordisk Investigational Site", "city": "Pori", "zip": "FI-28100", "country": "Finland", "geoPoint": {"lat": 61.48333, "lon": 21.78333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bar-Le-Duc", "zip": "55000", "country": "France", "geoPoint": {"lat": 48.78333, "lon": 5.16667}}, {"facility": "Novo Nordisk Investigational Site", "city": "GRENOBLE cedex", "zip": "38043", "country": "France", "geoPoint": {"lat": 45.16667, "lon": 5.71667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Hayange", "zip": "57700", "country": "France", "geoPoint": {"lat": 49.33428, "lon": 6.05267}}, {"facility": "Novo Nordisk Investigational Site", "city": "LA ROCHELLE cedex", "zip": "17019", "country": "France", "geoPoint": {"lat": 46.16667, "lon": -1.15}}, {"facility": "Novo Nordisk Investigational Site", "city": "Nanterre", "zip": "92014", "country": "France", "geoPoint": {"lat": 48.89198, "lon": 2.20675}}, {"facility": "Novo Nordisk Investigational Site", "city": "NEVERS cedex", "zip": "58033", "country": "France", "geoPoint": {"lat": 46.98956, "lon": 3.159}}, {"facility": "Novo Nordisk Investigational Site", "city": "Pointe \u00e0 Pitre", "zip": "97159", "country": "France"}, {"facility": "Novo Nordisk Investigational Site", "city": "Berlin", "zip": "12163", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"facility": "Novo Nordisk Investigational Site", "city": "Pirna", "zip": "01796", "country": "Germany", "geoPoint": {"lat": 50.95843, "lon": 13.93702}}, {"facility": "Novo Nordisk Investigational Site", "city": "Riesa", "zip": "01587", "country": "Germany", "geoPoint": {"lat": 51.30777, "lon": 13.29168}}, {"facility": "Novo Nordisk Investigational Site", "city": "Saarbr\u00fccken", "zip": "66121", "country": "Germany", "geoPoint": {"lat": 49.23262, "lon": 7.0098}}, {"facility": "Novo Nordisk Investigational Site", "city": "St. Ingbert", "zip": "66386", "country": "Germany"}, {"facility": "Novo Nordisk Investigational Site", "city": "V\u00f6lklingen", "zip": "66333", "country": "Germany", "geoPoint": {"lat": 49.25162, "lon": 6.85873}}, {"facility": "Novo Nordisk Investigational Site", "city": "Wangen", "zip": "88239", "country": "Germany", "geoPoint": {"lat": 48.72933, "lon": 9.61175}}, {"facility": "Novo Nordisk Investigational Site", "city": "Bydgoszcz", "zip": "85-822", "country": "Poland", "geoPoint": {"lat": 53.1235, "lon": 18.00762}}, {"facility": "Novo Nordisk Investigational Site", "city": "Gniewkowo", "zip": "88-140", "country": "Poland", "geoPoint": {"lat": 52.89461, "lon": 18.40785}}, {"facility": "Novo Nordisk Investigational Site", "city": "Nysa", "zip": "48-300", "country": "Poland", "geoPoint": {"lat": 50.47379, "lon": 17.33437}}, {"facility": "Novo Nordisk Investigational Site", "city": "Plock", "zip": "09-400", "country": "Poland", "geoPoint": {"lat": 52.54682, "lon": 19.70638}}, {"facility": "Novo Nordisk Investigational Site", "city": "Szczecin", "zip": "70-483", "country": "Poland", "geoPoint": {"lat": 53.42894, "lon": 14.55302}}, {"facility": "Novo Nordisk Investigational Site", "city": "Tychy", "zip": "43-100", "country": "Poland", "geoPoint": {"lat": 50.13717, "lon": 18.96641}}, {"facility": "Novo Nordisk Investigational Site", "city": "Warszawa", "zip": "02-507", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Novo Nordisk Investigational Site", "city": "Wroclaw", "zip": "50-127", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Novo Nordisk Investigational Site", "city": "Almer\u00eda", "zip": "04001", "country": "Spain", "geoPoint": {"lat": 36.83814, "lon": -2.45974}}, {"facility": "Novo Nordisk Investigational Site", "city": "Barcelona", "zip": "08035", "country": "Spain", "geoPoint": {"lat": 41.38879, "lon": 2.15899}}, {"facility": "Novo Nordisk Investigational Site", "city": "Granada", "zip": "18012", "country": "Spain", "geoPoint": {"lat": 37.18817, "lon": -3.60667}}, {"facility": "Novo Nordisk Investigational Site", "city": "Madrid", "zip": "28034", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"facility": "Novo Nordisk Investigational Site", "city": "San Juan", "zip": "03550", "country": "Spain"}]}, "referencesModule": {"references": [{"pmid": "22660026", "type": "RESULT", "citation": "Niskanen L, Leiter LA, Franek E, Weng J, Damci T, Munoz-Torres M, Donnet JP, Endahl L, Skjoth TV, Vaag A. Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial. Eur J Endocrinol. 2012 Aug;167(2):287-94. doi: 10.1530/EJE-12-0293. Epub 2012 Jun 1. Erratum In: Eur J Endocrinol. 2012 Sep;167(3):453."}, {"pmid": "22946603", "type": "RESULT", "citation": "Ma Z, Parkner T, Christiansen JS, Laursen T. IDegAsp: a novel soluble insulin analogs combination. Expert Opin Biol Ther. 2012 Nov;12(11):1533-40. doi: 10.1517/14712598.2012.722203. Epub 2012 Sep 4."}], "seeAlsoLinks": [{"label": "Clinical Trials at Novo Nordisk", "url": "http://novonordisk-trials.com"}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Subjects underwent a run-in period of up to 3 weeks (including 1-week maintenance period) where metformin was up-titrated to 1500 or 2000 mg/day. Subjects who tolerated metformin dose for a week and had fasting plasma glucose \u2265 7.5 mmol/L were randomised to SIAC 30 (B), SIAC 45 (B) or BIAsp 30 twice daily.", "recruitmentDetails": "The trial was conducted at 27 sites in 5 countries: Finland (4), France (4), Germany (6), Poland (9) and Spain (4).", "groups": [{"id": "FG000", "title": "SIAC 30 (B)", "description": "Soluble Insulin Analogue Combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "FG001", "title": "SIAC 45 (B)", "description": "Soluble Insulin Analogue Combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "FG002", "title": "BIAsp 30", "description": "Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "61"}, {"groupId": "FG001", "numSubjects": "59"}, {"groupId": "FG002", "numSubjects": "62"}]}, {"type": "Exposed", "achievements": [{"groupId": "FG000", "comment": "One subject withdrew prior to exposure to trial drug", "numSubjects": "60"}, {"groupId": "FG001", "numSubjects": "59"}, {"groupId": "FG002", "numSubjects": "62"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "54"}, {"groupId": "FG001", "numSubjects": "54"}, {"groupId": "FG002", "numSubjects": "57"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Unclassified", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "SIAC 30 (B)", "description": "Soluble Insulin Analogue Combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "BG001", "title": "SIAC 45 (B)", "description": "Soluble Insulin Analogue Combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "BG002", "title": "BIAsp 30", "description": "Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "61"}, {"groupId": "BG001", "value": "59"}, {"groupId": "BG002", "value": "62"}, {"groupId": "BG003", "value": "182"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "58.7", "spread": "8.5"}, {"groupId": "BG001", "value": "60.5", "spread": "8.9"}, {"groupId": "BG002", "value": "59.7", "spread": "8.0"}, {"groupId": "BG003", "value": "59.6", "spread": "8.4"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "23"}, {"groupId": "BG003", "value": "85"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "29"}, {"groupId": "BG001", "value": "29"}, {"groupId": "BG002", "value": "39"}, {"groupId": "BG003", "value": "97"}]}]}]}, {"title": "Glycosylated haemoglobin (HbA1c)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "percentage of glycosylated haemoglobin", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "8.5", "spread": "1.2"}, {"groupId": "BG001", "value": "8.5", "spread": "0.9"}, {"groupId": "BG002", "value": "8.6", "spread": "1.0"}, {"groupId": "BG003", "value": "8.5", "spread": "1.1"}]}]}]}, {"title": "Fasting plasma glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mmol/L", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "11.4", "spread": "2.7"}, {"groupId": "BG001", "value": "11.8", "spread": "2.9"}, {"groupId": "BG002", "value": "11.7", "spread": "3.1"}, {"groupId": "BG003", "value": "11.6", "spread": "2.9"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in Glycosylated Haemoglobin (HbA1c)", "description": "Change from baseline in HbA1c after 16 weeks of treatment", "populationDescription": "The full analysis set (FAS) included all randomised subjects and missing data was imputed using last observation carried forward (LOCF). HbA1c values were missing for 2 subjects, hence did not contribute to the analysis", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percentage of glycosylated haemoglobin", "timeFrame": "Week 0, Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble Insulin Analogue Combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble Insulin Analogue Combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "BIAsp 30", "description": "Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "58"}, {"groupId": "OG002", "value": "62"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-1.79", "spread": "1.11"}, {"groupId": "OG001", "value": "-1.87", "spread": "0.91"}, {"groupId": "OG002", "value": "-1.84", "spread": "0.93"}]}]}]}, {"type": "SECONDARY", "title": "Mean of 9-point Self Measured Plasma Glucose Profile (SMPG)", "description": "Estimate of the overall mean of SMPG after 16 weeks of treatment. Plasma glucose measured: before breakfast, 120 minutes after start of breakfast, before lunch, 120 minutes after start of lunch, before dinner, 120 minutes after start of dinner, before bedtime, at 4 am and before breakfast.", "populationDescription": "The full analysis set (FAS) included all randomised subjects and missing data was imputed using last observation carried forward (LOCF). For 2 subjects, mean SMPG values were missing.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mmol/L", "timeFrame": "Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble Insulin Analogue Combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble Insulin Analogue Combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "BIAsp 30", "description": "Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "58"}, {"groupId": "OG002", "value": "62"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.52", "spread": "0.27"}, {"groupId": "OG001", "value": "7.44", "spread": "0.28"}, {"groupId": "OG002", "value": "7.52", "spread": "0.27"}]}]}]}, {"type": "SECONDARY", "title": "Rate of Major and Minor Hypoglycaemic Episodes", "description": "Observed rate of major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L.", "populationDescription": "The full analysis set (FAS) included all randomised subjects.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Episodes/100 years of patient exposure", "timeFrame": "Week 0 to Week 16 + 5 days follow up", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble Insulin Analogue Combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble Insulin Analogue Combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "BIAsp 30", "description": "Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}]}], "classes": [{"title": "Major", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "287"}, {"groupId": "OG001", "value": "679"}, {"groupId": "OG002", "value": "730"}]}]}]}, {"type": "SECONDARY", "title": "Rate of Nocturnal Major and Minor Hypoglycaemic Episodes", "description": "Rate of nocturnal major and minor hypoglycaemic episodes per 100 patient years of exposure (PYE). Major if unable to treat her/himself. Minor if able to treat her/himself and plasma glucose below 3.1 mmol/L. Episodes were defined as nocturnal if the time of onset was between 23:00 (included) and 05:59 (included).", "populationDescription": "The full analysis set (FAS) included all randomised subjects.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Episodes/100 years of patient exposure", "timeFrame": "Week 0 to Week 16 + 5 days follow up", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble Insulin Analogue Combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble Insulin Analogue Combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "BIAsp 30", "description": "Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "61"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}]}], "classes": [{"title": "Major", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Minor", "categories": [{"measurements": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "79"}, {"groupId": "OG002", "value": "108"}]}]}]}, {"type": "SECONDARY", "title": "Rate of Treatment Emergent Adverse Events (AEs)", "description": "Corresponds to rate of AEs per 100 patient years of exposure. Severity assessed by investigator. Mild: no or transient symptoms, no interference with subject's daily activities. Moderate: marked symptoms, moderate interference with subject's daily activities. Severe: considerable interference with subject's daily activities, unacceptable. Serious AE: AE that at any dose results in any of the following: death, a life-threatening experience, in-subject hospitalization/prolongation of existing hospitalisation, persistent/significant disability/incapacity/congenital anomaly/birth defect.", "populationDescription": "The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Events/100 years of patient exposure", "timeFrame": "Week 0 to Week 16 + 5 days follow up", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble Insulin Analogue Combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble Insulin Analogue Combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "BIAsp 30", "description": "Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}]}], "classes": [{"title": "Adverse events (AEs)", "categories": [{"measurements": [{"groupId": "OG000", "value": "298"}, {"groupId": "OG001", "value": "545"}, {"groupId": "OG002", "value": "379"}]}]}, {"title": "Serious AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "11"}]}]}, {"title": "Severe AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Moderate AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "56"}, {"groupId": "OG001", "value": "67"}, {"groupId": "OG002", "value": "38"}]}]}, {"title": "Mild AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "242"}, {"groupId": "OG001", "value": "477"}, {"groupId": "OG002", "value": "335"}]}]}, {"title": "Fatal AEs", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "5"}]}]}]}, {"type": "SECONDARY", "title": "Laboratory Safety Parameters (Biochemistry): Alanine Aminotransferase (ALAT)", "description": "Laboratory values at screening (Week -4) and at Week 16", "populationDescription": "The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator. For 2 subjects the laboratory values were missing at week -4. From the SAS, 54 (SIAC 30), 57 (SIAC 45) and 53 (BIAsp 30) subjects contributed to the analysis at week 16.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "IU/L", "timeFrame": "Week -4, Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble Insulin Analogue Combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble Insulin Analogue Combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "BIAsp 30", "description": "Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}]}], "classes": [{"title": "Week -4, N=60, 57, 62", "categories": [{"measurements": [{"groupId": "OG000", "value": "33.0", "spread": "16.6"}, {"groupId": "OG001", "value": "31.4", "spread": "16.0"}, {"groupId": "OG002", "value": "36.9", "spread": "23.4"}]}]}, {"title": "Week 16, N=54, 57, 53", "categories": [{"measurements": [{"groupId": "OG000", "value": "22.9", "spread": "9.2"}, {"groupId": "OG001", "value": "22.5", "spread": "11.1"}, {"groupId": "OG002", "value": "23.6", "spread": "11.3"}]}]}]}, {"type": "SECONDARY", "title": "Laboratory Safety Parameters (Biochemistry): Aspartate Aminotransferase (ASAT)", "description": "Laboratory values at screening (Week -4) and at Week 16", "populationDescription": "The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator. For 3 subjects the laboratory values were missing at week -4. From the SAS, 54 (SIAC 30), 57 (SIAC 45) and 53 (BIAsp 30) subjects contributed to the analysis at week 16.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "IU/L", "timeFrame": "Week -4, Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble Insulin Analogue Combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble Insulin Analogue Combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "BIAsp 30", "description": "Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}]}], "classes": [{"title": "Week -4, N=60, 56, 62", "categories": [{"measurements": [{"groupId": "OG000", "value": "23.6", "spread": "11.2"}, {"groupId": "OG001", "value": "25.2", "spread": "12.0"}, {"groupId": "OG002", "value": "26.4", "spread": "16.1"}]}]}, {"title": "Week 16, N=54, 57, 53", "categories": [{"measurements": [{"groupId": "OG000", "value": "22.6", "spread": "8.7"}, {"groupId": "OG001", "value": "22.9", "spread": "11.4"}, {"groupId": "OG002", "value": "23.1", "spread": "11.2"}]}]}]}, {"type": "SECONDARY", "title": "Laboratory Safety Parameters (Biochemistry): Serum Creatinine", "description": "Laboratory values at screening (Week -4) and at Week 16", "populationDescription": "The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator. For 2 subjects the laboratory values were missing at week -4. From the SAS, 56 (SIAC 30), 57 (SIAC 45) and 56 (BIAsp 30) subjects contributed to the analysis at week 16.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "umol/L", "timeFrame": "Week -4, Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble Insulin Analogue Combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble Insulin Analogue Combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "BIAsp 30", "description": "Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}]}], "classes": [{"title": "Week -4, N=60, 57, 62", "categories": [{"measurements": [{"groupId": "OG000", "value": "72.7", "spread": "14.0"}, {"groupId": "OG001", "value": "75.8", "spread": "14.8"}, {"groupId": "OG002", "value": "74.8", "spread": "14.1"}]}]}, {"title": "Week 16, N=56, 57, 56", "categories": [{"measurements": [{"groupId": "OG000", "value": "73.6", "spread": "13.2"}, {"groupId": "OG001", "value": "76.3", "spread": "16.1"}, {"groupId": "OG002", "value": "78.1", "spread": "15.5"}]}]}]}, {"type": "SECONDARY", "title": "Vital Signs: Diastolic Blood Pressure (BP)", "description": "Values at baseline (Week 0) and at Week 16", "populationDescription": "The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator. From the SAS, 58 (SIAC 30), 56 (SIAC 45) and 58 (BIAsp 30) subjects contributed to the analysis at week 16.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Week 0, Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble Insulin Analogue Combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble Insulin Analogue Combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "BIAsp 30", "description": "Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}]}], "classes": [{"title": "Week 0 (Baseline), N=60, 59, 62", "categories": [{"measurements": [{"groupId": "OG000", "value": "80", "spread": "9"}, {"groupId": "OG001", "value": "81", "spread": "10"}, {"groupId": "OG002", "value": "81", "spread": "11"}]}]}, {"title": "Week 16, N=58, 56, 58", "categories": [{"measurements": [{"groupId": "OG000", "value": "78", "spread": "9"}, {"groupId": "OG001", "value": "79", "spread": "10"}, {"groupId": "OG002", "value": "76", "spread": "9"}]}]}]}, {"type": "SECONDARY", "title": "Vital Signs: Systolic Blood Pressure (BP)", "description": "Values at baseline (Week 0) and at Week 16", "populationDescription": "The safety analysis set includes all subjects who received at least one dose of the investigational product or its comparator. From the SAS, 58 (SIAC 30), 56 (SIAC 45) and 58 (BIAsp 30) subjects contributed to the analysis at week 16.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mmHg", "timeFrame": "Week 0, Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble Insulin Analogue Combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble Insulin Analogue Combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "BIAsp 30", "description": "Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}]}], "classes": [{"title": "Week 0 (Baseline), N=60, 59, 62", "categories": [{"measurements": [{"groupId": "OG000", "value": "134", "spread": "15"}, {"groupId": "OG001", "value": "138", "spread": "18"}, {"groupId": "OG002", "value": "137", "spread": "18"}]}]}, {"title": "Week 16, N=58, 56, 58", "categories": [{"measurements": [{"groupId": "OG000", "value": "128", "spread": "13"}, {"groupId": "OG001", "value": "135", "spread": "17"}, {"groupId": "OG002", "value": "133", "spread": "15"}]}]}]}, {"type": "SECONDARY", "title": "Vital Signs: Pulse", "description": "Values at baseline (Week 0) and at Week 16", "populationDescription": "The safety analysis set included all subjects who received at least one dose of the investigational product or its comparator. From the SAS, 58 (SIAC 30), 56 (SIAC 45) and 58 (BIAsp 30) subjects contributed to the analysis at week 16.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "beats/minute", "timeFrame": "Week 0, Week 16", "groups": [{"id": "OG000", "title": "SIAC 30 (B)", "description": "Soluble Insulin Analogue Combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 45 (B)", "description": "Soluble Insulin Analogue Combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "BIAsp 30", "description": "Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "60"}, {"groupId": "OG001", "value": "59"}, {"groupId": "OG002", "value": "62"}]}], "classes": [{"title": "Week 0 (Baseline), N=60, 59, 62", "categories": [{"measurements": [{"groupId": "OG000", "value": "74", "spread": "10"}, {"groupId": "OG001", "value": "76", "spread": "8"}, {"groupId": "OG002", "value": "75", "spread": "8"}]}]}, {"title": "Week 16, N=58, 56, 58", "categories": [{"measurements": [{"groupId": "OG000", "value": "73", "spread": "10"}, {"groupId": "OG001", "value": "73", "spread": "8"}, {"groupId": "OG002", "value": "77", "spread": "9"}]}]}]}, {"type": "SECONDARY", "title": "Physical Examination", "description": "Physical examination was performed at screening (week -4), and after 8 and 16 weeks of treatment. If any new findings or deterioration in previous findings were observed during the trial, these were recorded as AEs and are therefore not presented separately as no analysis was performed.", "reportingStatus": "POSTED", "timeFrame": "Week -4, Week 8, Week 16", "groups": [{"id": "OG000", "title": "BIAsp 30", "description": "Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG001", "title": "SIAC 30 (B)", "description": "Soluble Insulin Analogue Combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}, {"id": "OG002", "title": "SIAC 45 (B)", "description": "Soluble Insulin Analogue Combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "The adverse events were collected in a time frame of 16 weeks + 5 days follow up", "description": "The safety analysis set included all subjects with exposure information of at least one dose of randomised trial medication.", "eventGroups": [{"id": "EG000", "title": "SIAC 30 (B)", "description": "Soluble Insulin Analogue Combination 30 (SIAC 30, 70 volume percent insulin degludec, 600 nmol/ml and 30 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted.", "seriousNumAffected": 0, "seriousNumAtRisk": 60, "otherNumAffected": 14, "otherNumAtRisk": 60}, {"id": "EG001", "title": "SIAC 45 (B)", "description": "Soluble Insulin Analogue Combination 45 (SIAC 45, 55 volume percent insulin degludec, 600 nmol/ml and 45 volume percent insulin aspart, 600 nmol/ml \\[1 dosing unit = 6 nmol\\]); formulation B) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted.", "seriousNumAffected": 0, "seriousNumAtRisk": 59, "otherNumAffected": 13, "otherNumAtRisk": 59}, {"id": "EG002", "title": "BIAsp 30", "description": "Biphasic insulin aspart 30 (BIAsp 30) was given subcutaneously twice daily before breakfast and dinner in combination with at least 1500 mg metformin (tablets) for 16 weeks. Insulin doses were individually adjusted.", "seriousNumAffected": 2, "seriousNumAtRisk": 62, "otherNumAffected": 13, "otherNumAtRisk": 62}], "seriousEvents": [{"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}]}], "otherEvents": [{"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 9, "numAffected": 8, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 62}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 7, "numAffected": 3, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 62}]}, {"term": "Back pain", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 4, "numAffected": 1, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 7, "numAffected": 4, "numAtRisk": 62}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 10, "numAffected": 6, "numAtRisk": 60}, {"groupId": "EG001", "numEvents": 7, "numAffected": 5, "numAtRisk": 59}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 62}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Novo Nordisk maintains the right to be informed of any Investigator plans for publication and to review any scientific paper, presentation, communication or other information concerning the investigation described in this protocol. Any such communication must be submitted in writing to the Novo Nordisk trial manager prior to submission for comments. Comments will be given within four weeks from receipt of the planned communication."}, "pointOfContact": {"title": "Public Access to Clinical Trials", "organization": "Novo Nordisk A/S", "email": "clinicaltrials@novonordisk.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Diabetes Mellitus, Type 2", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000007328", "term": "Insulin"}, {"id": "C000557859", "term": "Insulin, Globin Zinc"}, {"id": "D000008687", "term": "Metformin"}, {"id": "D000061267", "term": "Insulin Aspart"}, {"id": "D000049528", "term": "Insulin, Long-Acting"}, {"id": "C000578220", "term": "Insulin degludec, insulin aspart drug combination"}, {"id": "D000061265", "term": "Biphasic Insulins"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}], "browseLeaves": [{"id": "M10365", "name": "Insulin", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M173166", "name": "Insulin, Globin Zinc", "asFound": "Blood", "relevance": "HIGH"}, {"id": "M29801", "name": "Insulin Aspart", "asFound": "Obtained", "relevance": "HIGH"}, {"id": "M29799", "name": "Biphasic Insulins", "asFound": "Institutional", "relevance": "HIGH"}, {"id": "M17768", "name": "Zinc", "relevance": "LOW"}, {"id": "M26073", "name": "Insulin, Long-Acting", "asFound": "Epinephrine", "relevance": "HIGH"}, {"id": "M117006", "name": "Insulin degludec, insulin aspart drug combination", "asFound": "Obtained", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Micro", "name": "Micronutrients"}]}}, "hasResults": true}